查看購物車
  • Simplified Chinese
  • English
  • Japanese
歐洲青光眼治療市場預測（2031年）-區域分析-依藥物類別、適應症及配銷通路
市場調查報告書
商品編碼
1764897

歐洲青光眼治療市場預測（2031年）-區域分析-依藥物類別、適應症及配銷通路

Europe Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 133 Pages | 訂單完成後即時交付

價格

2023 年歐洲青光眼治療市場價值為 15.2983 億美元，預計到 2031 年將達到 19.3078 億美元；預計 2023 年至 2031 年的複合年成長率為 3.0%。

越來越多的產品發布、合作和收購推動了歐洲青光眼治療市場的發展

青光眼治療藥物製造商正在實施策略聯盟、地理擴張、合作夥伴關係、併購和產品/服務發布等策略，以彰顯其在市場上的地位。

2024 年 3 月，專門從事創新眼部藥物傳輸技術的公司 MediPrint Ophthalmics 宣布成功完成其 2b 期青光眼 SIGHT-2 研究。

2023年12月，美國食品藥物管理局（FDA）批准了Glaukos公司iDose TR（曲伏前列素前房植入劑）75微克的新藥申請（NDA）。 iDose TR是一種前列腺素類似物，用於降低眼高壓症（OHT）或開角型青光眼（OAG）患者的眼壓。該藥物獲準每眼單次給藥。

2022年11月，愛爾康收購了Aerie Pharmaceuticals, Inc.。透過此次收購，愛爾康獲得了Rocklatan（奈他舒地爾和拉坦前列素滴眼液）0.02%/0.005%；Rhopressa（奈他舒地爾滴眼液）0.02%；AR-15512（用於治療乾眼症的III期候選產品）；以及一系列臨床候選藥物和臨床階段的臨床候選藥物。 Rocklatan和Rhopressa皆為Rho激酶抑制劑，用於降低開角型青光眼或高眼壓症患者的眼壓升高。此次收購使愛爾康在拓展其產品組合方面邁出了一步，將青光眼、視網膜和眼表疾病治療藥物納入其中。

2022年3月，強生視力保健公司（Johnson & Johnson Vision Care, Inc.）旗下新款ACUVUE Theravision隱形眼鏡獲得美國食品藥品監督管理局（FDA）批准，該款隱形眼鏡含有抗組織胺藥酮替芬（每片19微克）。含酮替芬的ACUVUE Theravision隱形眼鏡是同類產品中的首款產品，旨在為出現過敏性眼癢的隱形眼鏡使用者帶來全新的配戴體驗。此類產品發布、合作和收購對青光眼治療市場的成長做出了重大貢獻。

歐洲青光眼治療市場概況

歐洲青光眼治療市場分為德國、法國、英國、西班牙、義大利和歐洲其他地區。德國和義大利等國家為該地區的市場貢獻了相當大的佔有率，而法國、英國和西班牙等國家則可能為青光眼治療市場參與者帶來巨大的成長機會。歐洲青光眼治療市場的成長歸因於隨著人口老化加劇，青光眼病例數量不斷增加。德國是青光眼發生率較高的國家。根據薩貝爾視力恢復中心 (SAVIR) 的數據，該國約有 50 萬人患有青光眼。然而，專家估計，由於未報告的病例，實際數字可能要高得多。近 10% 的青光眼患者最終會出現嚴重的視力障礙；儘管如此，幾乎沒有人會完全失明。根據聯邦統計局 (Destatis) 的數據，截至 2021 年底，德國 67 歲及以上人口將達到 1,620 萬，預計到 2060 年這一數字將增至 2,160 萬。隨著年齡的成長，患青光眼和其他眼部疾病的機率可能會增加。因此，老年人口激增導致青光眼盛行率大幅上升，從而推動了德國各地對青光眼治療藥物的需求。

歐洲青光眼治療市場收入及預測（2031年）（百萬美元）

歐洲青光眼治療市場細分

歐洲青光眼治療市場按藥物類別、適應症、配銷通路和國家分類。

依藥物類別，歐洲青光眼治療市場細分為BETA受體阻斷劑、α腎上腺素激動劑、前列腺素類似物、碳酸酐酶抑制劑、複方藥物及其他。前列腺素類似物在2023年佔據了最大的市場。

根據適應症，歐洲青光眼治療市場分為開角型青光眼、閉角型青光眼和其他類型。 2023年，開角型青光眼佔了最大的市場。

根據配銷通路，歐洲青光眼治療市場分為醫院藥房、零售藥房和線上藥房。 2023年，醫院藥局佔了最大的市場佔有率。

按國家/地區分類，歐洲青光眼治療市場分為德國、法國、義大利、英國、西班牙和歐洲其他地區。 2023年，德國佔據了歐洲青光眼治療市場的主導地位。

Alcon AG、AbbVie Inc、Bausch & Lomb Inc, LLC、Viatris Inc、Novartis AG、Sun Pharmaceutical Industries Ltd、Teva Pharmaceuticals Industries Ltd、Thea Pharma Inc 和 Santen Pharmaceutical Co., Ltd. 是歐洲青光眼治療市場的主要公司。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力

第3章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 顯影基數：
    • 數據三角測量：
    • 國家級資料：

第4章：歐洲青光眼治療市場-關鍵市場動態

  • 青光眼治療市場－關鍵市場動態
  • 市場促進因素
    • 青光眼發生率不斷上升
    • 產品發布、合作和收購的數量不斷增加
  • 市場限制
    • 藥物治療方案依從性問題
  • 市場機會
    • 穿戴式科技的發展
  • 未來趨勢
    • 新型藥物輸送方法的開發
  • 促進因素和限制因素的影響：

第5章：青光眼治療市場－歐洲分析

  • 2021-2031年青光眼治療市場收入
  • 青光眼治療市場預測分析

第6章：歐洲青光眼治療市場分析－依藥物類別

  • BETA受體阻斷劑
  • α腎上腺素激動劑
  • 前列腺素類似物
  • 碳酸酐酶抑制劑
  • 聯合用藥
  • 其他

第7章：歐洲青光眼治療市場分析－按適應症

  • 開角型青光眼
  • 閉角型青光眼
  • 其他

第8章：歐洲青光眼治療市場分析－按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第9章：歐洲青光眼治療市場-國家分析

  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 歐洲其他地區

第 10 章：青光眼治療市場-產業格局

  • 青光眼治療市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 11 章：公司簡介

  • Alcon AG
  • AbbVie Inc
  • Bausch & Lomb Inc
  • Viatris Inc
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Thea Pharma Inc
  • Santen Pharmaceutical Co., Ltd.

第 12 章：附錄

Product Code: BMIRE00031611

The Europe glaucoma therapeutics market was valued at US$ 1,529.83 million in 2023 and is expected to reach US$ 1,930.78 million by 2031; it is estimated to register a CAGR of 3.0% from 2023 to 2031.

Increasing Number of Product Launches, Collaborations, and Acquisitions Fuels Europe Glaucoma Therapeutics Market

Glaucoma therapeutics manufacturers are implementing strategies such as strategic alliances, geographic expansions, partnerships, mergers & acquisitions, and product/service launches to mark their presence in the market.

In March 2024, MediPrint Ophthalmics, a company that specializes in innovative ocular drug delivery technologies, announced the successful completion of its Phase 2b Glaucoma SIGHT-2 study.

In December 2023, the US Food and Drug Administration (FDA) approved Glaukos Corporation's New Drug Application (NDA) for iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of IOP in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). The drug was approved for a single administration per eye.

In November 2022, Alcon acquired Aerie Pharmaceuticals, Inc. Through the transaction, Alcon acquired Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%; Rhopressa (netarsudil ophthalmic solution) 0.02%; AR-15512, a Phase 3 product candidate for dry eye disease; and a pipeline of several preclinical and clinical ophthalmic pharmaceutical product candidates. Rocklatan and Rhopressa are Rho-kinase inhibitors indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. With this acquisition, Alcon takes a step forward to broaden its portfolio with the inclusion of glaucoma, and retinal and ocular surface disease therapeutics.

In March 2022, Johnson & Johnson Vision Care, Inc. received FDA approval for its new ACUVUE Theravision variant, a type of contact lens containing an antihistamine called ketotifen (19 µg per lens). ACUVUE Theravision with Ketotifen is the first of its kind and is designed to provide a new wearing experience for contact lens users, experiencing allergic eye itch. Such product launches, collaborations, and acquisitions contribute significantly to the growth of the glaucoma therapeutics market.

Europe Glaucoma Therapeutics Market Overview

The Europe glaucoma therapeutics market is segmented into Germany, France, the UK, Spain, Italy, and the Rest of Europe. Countries such as Germany and Italy contribute significant shares to the market in this region, and countries such as France, the UK, and Spain are likely to present significant growth opportunities for glaucoma therapeutics market players. The Europe glaucoma therapeutics market growth is ascribed to the rising number of glaucoma cases with the increasing aging population. Germany records a widespread occurrence of glaucoma. According to Sabel Vision Restoration Center (SAVIR), approximately half a million people are affected by glaucoma in this country. However, experts estimate that the actual number may be much higher due to unreported cases. Nearly 10% of all individuals suffering from glaucoma eventually experience serious vision impairments; nonetheless, almost none is likely to attain complete blindness. As per the Federal Statistical Office (Destatis), 16.2 million people in Germany were aged 67 and above by the end of 2021, and the number is projected to rise to 21.6 million by 2060. The probability of developing glaucoma and other eye diseases is likely to increase with aging. Thus, a significant prevalence of glaucoma due to the surging geriatric population propels the demand for glaucoma therapeutics across Germany.

Europe Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)

Europe Glaucoma Therapeutics Market Segmentation

The Europe glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.

Based on drug class, the Europe glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.

In terms of indication, the Europe glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.

By distribution channel, the Europe glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.

By country, the Europe glaucoma therapeutics market is segmented into Germany, France, Italy, the UK, Spain, and the Rest of Europe. Germany dominated the Europe glaucoma therapeutics market share in 2023.

Alcon AG, AbbVie Inc, Bausch & Lomb Inc, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the Europe glaucoma therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Europe Glaucoma Therapeutics Market - Key Market Dynamics

  • 4.1 Glaucoma Therapeutics Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Mounting Incidence of Glaucoma Disease
    • 4.2.2 Increasing Number of Product Launches, Collaborations, and Acquisitions
  • 4.3 Market Restraints
    • 4.3.1 Medication Regimen Compliance Issues
  • 4.4 Market Opportunities
    • 4.4.1 Development of Wearable Technologies
  • 4.5 Future Trends
    • 4.5.1 Development of Novel Drug Delivery Methods
  • 4.6 Impact of Drivers and Restraints:

5. Glaucoma Therapeutics Market - Europe Analysis

  • 5.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • 5.2 Glaucoma Therapeutics Market Forecast Analysis

6. Europe Glaucoma Therapeutics Market Analysis - by Drug Class

  • 6.1 Beta Blockers
    • 6.1.1 Overview
    • 6.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.2 Alpha Adrenergic Agonists
    • 6.2.1 Overview
    • 6.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.3 Prostaglandins Analogues
    • 6.3.1 Overview
    • 6.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.4 Carbonic Anhydrase Inhibitors
    • 6.4.1 Overview
    • 6.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.5 Combination Drugs
    • 6.5.1 Overview
    • 6.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.6 Others
    • 6.6.1 Overview
    • 6.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

7. Europe Glaucoma Therapeutics Market Analysis - by Indication

  • 7.1 Open Angle Glaucoma
    • 7.1.1 Overview
    • 7.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Angle Closure Glaucoma
    • 7.2.1 Overview
    • 7.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Others
    • 7.3.1 Overview
    • 7.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

8. Europe Glaucoma Therapeutics Market Analysis - by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Overview
    • 8.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Retail Pharmacy
    • 8.2.1 Overview
    • 8.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Online Pharmacy
    • 8.3.1 Overview
    • 8.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

9. Europe Glaucoma Therapeutics Market - Country Analysis

  • 9.1 Europe
    • 9.1.1 Europe: Glaucoma Therapeutics Market Breakdown, by Key Country, 2023 and 2031 (%)
      • 9.1.1.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.2 Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.2.1 Germany: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.2.2 Germany: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.2.3 Germany: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.3 France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.3.1 France: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.3.2 France: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.3.3 France: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.4 United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.4.1 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.4.2 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.4.3 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.5 Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.5.1 Italy: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.5.2 Italy: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.5.3 Italy: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.6 Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.6.1 Spain: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.6.2 Spain: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.6.3 Spain: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.7 Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.7.1 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.7.2 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.7.3 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel

10. Glaucoma Therapeutics Market - Industry Landscape

  • 10.1 Growth Strategies in Glaucoma Therapeutics Market
  • 10.2 Organic Growth Strategies
    • 10.2.1 Overview
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview

11. Company Profiles

  • 11.1 Alcon AG
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 AbbVie Inc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Bausch & Lomb Inc
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Viatris Inc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Novartis AG
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Sun Pharmaceutical Industries Ltd
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Teva Pharmaceutical Industries Ltd
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Thea Pharma Inc
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Santen Pharmaceutical Co., Ltd.
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms

List Of Tables

  • Table 1. Europe Glaucoma Therapeutics Market Segmentation
  • Table 2. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 3. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 4. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 5. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 6. Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Country
  • Table 7. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 8. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 9. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 10. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 11. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 12. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 13. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 14. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 15. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 16. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 17. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 18. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 19. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 20. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 21. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 22. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 23. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 24. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 25. Recent Organic Growth Strategies in Glaucoma Therapeutics Market
  • Table 26. Recent Inorganic Growth Strategies in the Glaucoma Therapeutics Market
  • Table 27. Glossary of Terms

List Of Figures

  • Figure 1. Europe Glaucoma Therapeutics Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • Figure 4. Glaucoma Therapeutics Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 5. Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 6. Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Glaucoma Therapeutics Market Share (%) - by Indication (2023 and 2031)
  • Figure 12. Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Glaucoma Therapeutics Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 16. Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Europe Glaucoma Therapeutics Market, by Key Country - Revenue (2023) (US$ Million)
  • Figure 20. Europe: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 21. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Growth Strategies in Glaucoma Therapeutics Market